Semzuvolimab

Semzuvolimab is an experimental cancer drug developed by Innovent Biologics and Eli Lilly and Company. It is a monoclonal antibody designed to inhibit PD-1, a protein that plays a major role in suppressing the immune system. By blocking PD-1, semzuvolimab may help the immune system recognize and attack cancer cells.

Development and Clinical Trials

Semzuvolimab is currently in clinical trials for the treatment of various types of cancer. In a Phase 1 trial, the drug showed promising results in patients with advanced solid tumors. The trial found that semzuvolimab was well-tolerated and demonstrated anti-tumor activity.

Innovent and Eli Lilly are also conducting a Phase 3 trial to evaluate the efficacy and safety of semzuvolimab in combination with chemotherapy in patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

Mechanism of Action

Semzuvolimab works by binding to PD-1, a protein found on the surface of certain immune cells. PD-1 acts as a "brake" on the immune system, preventing it from attacking normal cells. However, some cancer cells can exploit this mechanism to avoid being targeted by the immune system. By blocking PD-1, semzuvolimab can potentially enhance the body's immune response against cancer cells.

Potential Side Effects

As with any drug, semzuvolimab may cause side effects. In clinical trials, the most common side effects were fatigue, decreased appetite, and nausea. Serious side effects, including immune-related adverse events, were also reported.

Future Prospects

If successful in clinical trials, semzuvolimab could offer a new treatment option for patients with advanced cancers. However, further research is needed to fully understand the drug's efficacy and safety profile.

Semzuvolimab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia